You may be eligible for a research study entitled "Surveillance and Treatment tO Prevent Fetal Atrioventricular Block Likely to Occur Quickly" (STOP BLOQ)
If eligible, you will be asked to participate in 3 steps:
A screening step to evaluate the level of autoantibodies to Ro52 and Ro60 (proteins in your blood).
This step occurs if you are found to have high levels of anti-Ro60 or Ro52 antibodies and involves weekly or biweekly echoes and listening to your baby’s heartbeat 3x/day. The listening to the heart is called Fetal Heart Rate Monitoring.
A treatment step consisting of dexamethasone and IVIG if heart block develops.
If you would like to know more about the study, please contact one of our study coordinators, or find a participating center near you.
*The study is voluntary
Clinical trials.gov identifier NCT04474223. Funded by NICHD RO1HD100929. Study ID/NYU IRB S20-00363.